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BACKGROUND: Peptidoglycan monomer (PGM), which
was originally prepared by biosynthesis from culture
fluids of penicillin-treated Brevibacterium divarica-
tum, is an immunostimulator, the activities of which
might be improved by addition of zinc (Zn) to the
basic molecule.
Methods: To test the possible cytotoxic effects of this
new analogue, we analyzed the ability of PGM-Zn and
PGM to change the phenotypic profile of hepatic and
splenic mononuclear lymphatic cells and to affect the
growth of malignant T-cell line YAC-1 and syngeneic
thymocytes.
Results: Pretreatment of C57BL/6 mice primarily with
PGM-Zn over 6 days (10/mg/kg intraperitoneally)
significantly enhanced the proportions of NK1.1high+,
CD4–CD8–, CD69+, and CD3intermediate/NK1.1+/IL2R-b+
(NKT) cells in the liver, and major histocompatibility
complex class II+, CD69+, and CD8+ cells in the spleen.
Both types of cells were highly cytotoxic against YAC-
1 and syngeneic thymocytes, increasing the destruc-
tion of YAC-1 by 70% on addition of hepatic cells and
by 30% on addition of splenic cells. Destruction of
thymocytes increased by 10 and 50%, respectively.
Conclusion: The results point to PGM-Zn as a potent
cytotoxicity-inducing agent, which also generates
autoreactive NKT cells.
Key words: NK cells, NK1.1, Intermediate T cell receptor
expressing cells, Cytotoxicity to YAC-1 and syngeneic
thymocytes, Liver and spleen, Self-reacting NKT cells
Introduction
Bacterial cell-wall components, such as lipopoly-
saccharide derived from Gram-negative bacteria and
peptidoglycans (PG) isolated from Gram-positive bac-
terial cell walls, are well-known immunomodulating
agents, which participate in the immune reaction
generated on antigen or pathogen stimulation.1–6
Both substances in the presence of two soluble serum
proteins (i.e. CD14 and lipopolysaccharide binding
protein) activate lymphoid targets through the CD14
receptor, which might be viewed as the patterns
recognition receptor for various bacterial cell-wall
components.3,4 CD14 then recruits peptidoglycan
monomer (PGM) to members of Toll-like receptor
(TLR)2, which was identified as an essential compo-
nent of the PG receptor signaling complex that
controls innate responses.5–7
Stimulation of TLR proteins results in the release
mainly of pro-inflammatory mediators (interleukin
(IL)-1, IL-6, and tumor necrosis factor-a), which in
large quantities might promote infection and induce
septic shock.7 In lower doses, however, bacterial
products might have immunostimulating and anti-
metastatic activities linked with the stimulation of
both unspecific and specific immune responses.8
Adjuvant effects have been tried to be explained by
stimulation of co-stimulatory activities in antigen-
presenting cells, by mimicking of co-stimulatory
signals in T cells, or by enhanced uptake of the
antigen by dendritic cells that already express co-
stimulatory molecules.8 Since there is still a paucity of
data about the mechanisms leading to inflammatory
and immunomodulatory responses induced by Gram-
positive bacteria, in the present study we tested the
effects of PGM, obtained by biosynthesis from culture
fluids of penicillin-treated Brevibacterium divar-
icatum NRRL-2311,9 and its new analogue PGM-Zn
on the innate immune system.
Basically, PGM represents a water-soluble mono-
meric structural subunit of the polymeric PG, consist-
ing of b1,4-linked N-acetylmuramic acid-N-acetyl-
D-glucosamine disaccharide carrying the
pentapeptide. Its immunostimulating and antimeta-
static activities have been emphasized in many
experimental protocols,10–12 but the precise mecha-
nism of action of PGM is still unknown. Generally, it is
held that it uses similar pathways as other Gram-
positive bacteria.5,6This is supported also by our own
data, showing that PGM in vitro has a cytokine-
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stimulating power on human peripheral blood mono-
nuclear cells, leading to release of IL-1, IL-6, and
tumor necrosis factor-a in the presence of human
serum or soluble CD14.13 Previously, however, we
also reported that addition of zinc might potentiate
the immunostimulatory activity of PGM.14–17The new
analogue (PGM-Zn) augmented antibody production
and isotype switching in mice sensitized with sheep
red blood cells,14 and corrected some immunosup-
pressive aspects of aging15 and cholestatic jaundice.16
We also observed that prolonged treatment of mice
with PGM-Zn may result in activation of peritoneal
macrophages, which have greater phagocytic activ-
ities, as well as the ability to suppress the Con-
A-induced blastic transformation of syngeneic spleno-
cytes.17 Immunomodulatory effects of PGM and
PGM-Zn in these experiments correlated with major
histocompatibility complex (MHC) class II expression
in the liver,14 in which we also previously noticed an
accumulation of zinc during the normal humoral and
cellular immune response.18
Bearing in mind the crucial role of the hepatic
natural killer (NK) cells and NKT cells in the control
of immune survielance,19,20 and evidence about the
antitumor effects of PGM alone,10–12 in this study we
attempted to characterize the effects of PGM-Zn in
comparison with the effect of PGM alone on pro-
cesses of cell-mediated cytotoxicity. For this purpose,
we determined the phenotype and function of
hepatic and splenic mononuclear lymphatic cells
(MNLC) activated in vivo by PGM-Zn or PGM and
analyzed their ability to block the growth of the
malignant T-cell line YAC-1 and syngeneic thymocytes.
The data showed that pretreatment of C57BL/6 mice,
particularly with PGM-Zn, might markedly enhance
the cytotoxicity of both types of lymphoid cells
against NK-sensitive targets, as well as against synge-
neic cells. Simultaneous phenotypic analysis of effec-
tor cells also suggested that this cytotoxicity in the
liver might be linked with activation of NK1.1+,
CD3intermediate, IL-2Rb+ NKT cells, and in the spleen
with activation of cytotoxic CD8+ T cells.
Materials and methods
Animals
We used inbred, 2- to 3-month old, male C57BL/6
mice. The animals were housed in standard plastic
cages, allowed access to standard mouse food pellets
and water ad libitum, and exposed to the natural
light/dark cycle.
Treatment with PGM-Zn
Immunomodulating agents PGM (GlcNAc-MurNAc-
L-Ala-D-iso-Gln-meso-diamminopimelic acid (w-NH2)-
D-Ala-D-Ala) and PGM linked with zinc (PGM-Zn),
(Pliva, Zagreb, Croatia) were prepared by biosyn-
thesis from the culture fluids of Brevibacterium
divaricatum NRRL-2311, as an apyrogenic, water-
soluble substance devoid of any toxic effects.9 The
samples used in this study contained less than
0.015 ng of endotoxin/mg of PGM, according to the
limulus amebocyte lysate test (Pyrostat Kit; Millipore,
Bedford, Massachusetts). In the morning every sec-
ond day, the mice were injected with PGM-Zn or PGM
dissolved in phosphate-buffered saline (PBS) (10 mg/
kg of body weight, intraperitoneally (i.p.)) for 6 days
(total dose, 30 mg/kg). Mice in the control groups
were treated with the same volume (0.5 ml) of PBS.
Two days after the last injection, the animals were
sacrificed to isolate the hepatic and splenic MLNC.
Isolation of intrahepatic lymphocytes,
splenocytes and thymocytes
Intrahepatic lymphocytes (IHL) were isolated from
intact liver after in situ perfusion with PBS, using a
modification of the method of Seglen, as we pre-
viously described.21 Resident liver MNLC were iso-
lated by Ficoll–Hypaque density gradient centrifuga-
tion (20 min at 800 ´ g). A single suspension of spleen
cells was prepared in RPMI 1640 medium (Gipco BRL,
Basel, Switzerland), after elimination of erythrocytes
by lysing solution. The syngeneic thymocytes were
prepared in a similar way.
Cytofluorometric analysis
The surface phenotypes of resident IHL and spleno-
cytes were identified by direct immunofluorescence
analysis on FACScan (Becton Dickinson, Immunocyto-
metry Systems, Mountain View, CA, USA), using
CELLQuest Software (Quadra 650; Macintosh). As
primary monoclonal antibodies (mAbs), fluorescein
isothiocyanate-conjugated mAbs (anti-CD8, anti-CD3,
anti-class I, anti-class II and anti-T-cell receptor (anti-
TCR) ab) and phycoerythrin-conjugated mAbs (anti-
CD4, anti-CD25, anti-CD5, anti-CD44, anti-CD54, anti-
CD69, anti-CD30, anti-NK-1.1, and anti-TCR gd and
anti-IL2R-b chain) were used, purchased from Becton
Dickinson. All samples had adequate isotypic con-
trols. Propidium iodide (PI) (Sigma, St Louis, MO,
USA) (1 mg/ml) stained dead cells were excluded by
electronic gating. Relative fluorescence intensities
were expressed in the log scale, with 1 ´ 104 cells.
Flow cytometry cytotoxicity assay
Functional NK cell assays were performed with PKH-
26 (orange)-labeled YAC-1 or syngeneic thymocytes as
target cells following the manufacturer’s instructions
(PKH-26 Red Fluorescent Cell Linker Kit; Sigma
Biosciences, St Louis, MO, USA). For this purpose, IHL
and splenocytes were incubated for 2 h with 1 ´
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105/ml of labeled YAC-1 cells at different killer-to-target
ratios in a final volume of 200ml at 37°C in a 5% CO2
atmosphere. After washing in fluorescence-activated
cell sorter (FACS) medium, 200ml of PI (concentration,
10mg/ml) were added and the percentage of dead cells
was measured by flow cytometry. The destroyed cells
were counted by detecting cells with both orange
(PKH-26) and red (PI) fluorescence.
Statistical analysis
Data were analyzed using the Sigma Plot Scientific
Graphing System, Version 1.02. Statistical significance
was calculated by Mann–Whitney U test. The differ-
ences were considered significant when p < 0.05.
Results
Effects of PGM-Zn pretreatment on phenotypic
profile of MNLC in the liver and spleen
Six days after i.p. treatment with PGM-Zn (daily dose,
10 mg/kg), the proportion of several subtypes of
lymphoid cells in the liver and spleen had changed
(Fig. 1). The most prominent changes in the liver were
significant increases in the proportion of CD4–CD8–
(double negative), NK1.1high+, and CD69+ cells,
which increased from 55.5 ± 1.7 to 65.6 ± 3.1% (p <
0.05), from 27.8 ± 3.4 to 37.7 ± 2.5% (p < 0.01), and
from 35.3 ± 2.6 to 46.5 ± 2.6% (p < 0.01),
respectively. Double labeling, however, revealed that
most of PGM-Zn-induced hepatic MNLC belong to the
population of CD3int, NK1.1int, IL-2Rb+ cells (i.e.
typical NKT cells) (Fig. 2). Their percentage after the
PGM-Zn arose more than after treatment with PGM
alone (increase from 10.3% to 27.2%, or from 10.3% to
17.2%, respectively). In the spleen, however, sig-
nificant increases in the proportion of CD8+ (from
14.0 ± 0.3 to 16.3 ± 0.7%, p < 0.05), MHC class II+
(from 53.0 ± 2.6 to 60.3 ± 1.1%, p < 0.01), and CD69+
(from 1.5 ± 0.2 to 3 ± 0.3%, p < 0.05) cells were
observed, together with a decrease in the proportion
of CD3+ cells (from 37.1 ± 0.9 to 34 ± 0.6%, p < 0.01)
(Fig. 1). Double labeling also showed that PGM-Zn-
induced changes of NKT cells were in the spleen less
expressed than in the liver (Fig. 3). PGM alone in both
organs induced similar changes, but they were always
significantly lower that these obtained by PGM-Zn.
Cytotoxicity of hepatic and splenic MNLC
activated by PGM-Zn and PGM against YAC-1
To test the ability of PGM-Zn and PGM-activated
intrahepatic and splenic MNC to act against the NK-
sensitive malignant T-cell line YAC-1, labeled target
cells were exposed to killer cells in different killer-to-
target ratios (Fig. 4). The data, analyzed after 2 h,
showed that PGM-Zn increased, in a dose-dependent
manner, the cytotoxicity of both effectors, increasing
the destruction of YAC-1 by 70% after addition of
hepatic MLNC cells (from 5 to 76% at an effector:tar-
get ratio of 50:1, p < 0.01) and by 30% from baseline
after the addition of splenic cells (from 10 to 40%, p
< 0.05). Although PGM-activated intrahepatic and
splenic cells were more cytotoxic than control MNLC
(p < 0.01), this cytotoxicity at all ratios was sig-
nificantly lower than cytotoxicity of PGM-Zn-activated
cells (p < 0.01). A similar but less expressed stim-
ulatory effect was obtained with PGM-Zn-activated
peripheral blood mononuclear cells, which in the
control group showed very small cytotoxic activity
against YAC-1 (data not shown).
Cytotoxicity of hepatic and splenic MNLC
activated by PGM-Zn and PGM against
syngeneic thymocytes
To test the possibility that during the treatment of mice
with PGM-Zn or PGM autoreactive clones of NKT cells
were generated, hepatic and splenic MNLC were
incubated also with labeled syngeneic thymocytes
(Fig. 5). The data showed that PGM-Zn augmented the
cytotoxicity of hepatic MNLC by 10% (from 10 to 20%,
at an effector:target ratio of 50:1). Splenic MNLC,
obtained from PGM-Zn-treated mice, however, were
more cytotoxic for syngeneic thymocytes than control
MNLC, even at a very low effector:target ratio (50% at
the ratio 6.25:1, p < 0.01).
Cytotoxicity by PGM-Zn activated lymphoid cells
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FIG. 1. Phenotypic profiles of hepatic and splenic MNLC
obtained from C57BL/6 mice pretreated over 6 days with
three doses of PGM-Zn, PGM (10 mg/kg i.p.) or with saline
solution (n = 7). Mean ± standard errors are presented. *p <
0.05, **p < 0.01.
I. Mrakovcic- ÆSutic´ et al.
132 Mediators of Inflammation · Vol 11 · 2002
FIG. 2. FACS profiles of two-color immunofluorescence staining of hepatic MNLC after in vivo treatment with PGM-Zn, PGM
or medium, shown as a representative result of three isolated experiments.
FIG. 3. FACS profiles of two-color immunofluorescence staining of splenic MNLC after in vivo treatment with PGM-Zn, PGM or
medium, shown as a representative result of three isolated experiments.
Discussion
The data clearly show that PGM and especially PGM-
Zn, given in vivo, enhance the antitumor cytotox-
icity and autoreactivity of hepatic and splenic
MNLC. In the liver, the effect seems to be linked
with the increased proportion of activated CD3int
NK1.1+ cells, which after the treatment with PGM-
Zn were present in an almost threefold greater
proportion than in the control groups of mice (arose
from 10.28% to 27.19%). Almost all of them were
also IL-2Rb+ cells, although PGM-Zn increased also
the proportion of the NK1.1high+ and CD3– cell
populations (i.e. NK cells).
The described phenotype is characteristic for the
population of intermediate, NKT cells whose link
with the liver is particularly emphasized.19,20 Support-
ive elements of their differentiation is IL-7, which is
produced by hepatocytes, and IL-12, IL-15 and IL-18,
which are produced by Kupffer or endothelial
cells.22–24 Although NKT cells phenotypically repre-
sent marked heterogeneity, they usually co-express
markers that belong to T and NK lineage, and are
characterized by a highly restricted TCR repertoire,
made of an invariant TCRa chain, Va14-Ja281, asso-
ciated with polyclonal Vb8, Vb7, and Vb2 TCR b
chains.22–27 It was hypothesized that they represent
primordial T cells, which stay at an intermediate
phylogenetic position between NK-derived and thy-
mus-derived T cells.22,23The current dogma is that this
novel lineage of lymphocytes are selected by the non-
classical MHC class I-like molecule, CD1d, which in
mice is expressed on dendritic cells, B cells, T cells,
macrophages and hepatocytes.27,28 Unlike the con-
ventional MHC molecules, which bind short peptides
in their antigen-binding groove for presentation to
either CD4+ or CD8+T cells bearing abTCRs, the CD1
molecules are involved in the presentation of lipid
and glycolipid antigens.25–30The hydrophobic part of
these antigens most probably binds in the CD1 ligand-
binding groove, whereas the polar headgroup of these
antigens appears to make direct contact with the TCR
and determines specific recognition.29,30 In such a
way, CD1 molecules also display diverse, covalently
attached carbohydrates to T cells, that then help B
cells to mount an antibody response to polysacchar-
ide antigens.31 CD1-restricted NKT and T cells there-
fore play an important role in host defense against
microbial infection, but participate also in the recog-
nition of distinct self-antigens,28–32 since natural
Cytotoxicity by PGM-Zn activated lymphoid cells
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FIG. 4. Destruction of labeled YAC-1 target cells by hepatic
(A) and splenic (B) MNLC obtained from mice pretreated with
PGM-Zn or saline solution. Results are presented as mean ±
standard error (n = 7). *p < 0.05, **p < 0.01, ***p < 0.001.
FIG. 5. Destruction of labeled syngeneic target cells by
hepatic (A) and splenic (B) MNLC obtained from mice
pretreated with PGM-Zn or saline solution. Results are
presented as mean ± standard error (n = 7). *p < 0.05, **p <
0.01, ***p < 0.001.
ligands for CD1 molecules might be the glycosylphos-
phatidylinositol anchors and phosphoinositol manno-
sides,33 various metabolites produced by the cells,34
as well as stress proteins MICA and MICB,35 support-
ing the hypothesis that NKT cells represent autor-
eactive, forbidden, clones of T cells, which after
activation might eliminate abnormal self-cells.22–26
Our data showing increased cytotoxicity of hepatic
MNLC after in vivo treatment of mice with PGM-Zn
against NK-sensitive and syngeneic targets are, there-
fore, in agreement with current knowledge of induc-
tion and function of hepatic NKT cells in bacterial
infection.22,28,36 We are, however, among the first to
show that addition of Zn to PGM might potentiate
these activities. Owing to the relevance of zinc for
good functioning of the entire immune system, where
Zn is acting as a catalyst, structural (zinc fingers) and
regulatory ion,37–41 the observed effects obviously
might be obtained by different mechanisms.
Enhanced cytotoxicity probably includes the effect of
Zn2+ on the level of ‘NK cell immune synapse’, where
Zn modulates specifically the negative signal trans-
mitted to the NK cells, after binding of killer cell
immunoglobulin-like receptors to MHC class I pro-
teins.42,44 However, owing to the possibility that
PGM-Zn acts as superantigen, which markedly enhan-
ces the activities of T and B lymphocytes, it could be
hypothesized that some changes occurred also at the
level of MHC class II molecules, outside the peptide-
binding groove, since co-ordination of Zn2+ is
required for high binding of superantigen to this
place.44 Besides numerous other possibilities,37–41 we
would like also to emphasize the crucial role of zinc
for the regulation of apoptosis and cell prolifera-
tion,45,46 because this evidence permits one to
speculate that PGM-Zn was directly involved in the
apoptotic process and CD1 presentation of self-
antigens. Namely, during the infection, activated
monocytes and other cells undergo spontaneous
apoptosis, which involves Fas/Fas ligand interac-
tions.47–49 Moreover, since binding of bacterial toxins
and bacterial lipoproteins through TLR2 signals for
apoptosis through the myeloid differentiation factor
88 via a pathway involving Fas-associated death
domain protein and caspase 8, as well as for cytokine
production,50 there is a possibility that some of the
PGM-Zn-induced modifications of cell-mediated cyto-
toxicity occurred on the level of Toll-like receptor-2,
which is a ligand also for peptidoglycans, released
from Gram-positive bacteria.1–6 Furthermore, since it
is known that the intracellular content released from
dying cells may stimulate the generation of autor-
eactive NKT,24,27,32,33–35 as well as adaptive immune
responses,51 it could be speculated that, in such a
way, PGM-Zn has augmented also the cytotoxicity of
splenic MNLC to NK-sensitive and syngeneic targets
(Fig. 5). The recent finding of a high-speed commu-
nication network between the NKT cells, generated
in vivo after treatment with Alpha-GalCer, and the
adaptive immune systems52 seems to support this
conclusion.
Taken together, although the further character-
istics of the effects of PGM-Zn on innate immunity
remain to be elucidated, our data provide the first
evidence that addition of zinc to PGM markedly
enhances the generation of hepatic NKT cells and
increases the cytotoxic potential of hepatic and
splenic MNLC against NK-sensitive and syngeneic
targets.
ACKNOWLEDGMENTS. This work was supported by grants from the
Croatian Ministry of Science (project No 062002). The authors wish to
express their gratitude to the research staff of Pliva Pharmaceutical and
Chemical Works for donating the PGM-Zn used in the study.
References
1. Weidemann B, Schletter J, Dziarski R, et al. Specific binding of soluble
peptidoglycan and muramyldipeptide to CD14 on human monocytes.
Infect Immun 1997; 65: 858–864.
2. Henderson B, Poole S, Wilson M. Bacterial modulins: a novel class of
virulence factors which cause host tissue pathology by inducing
cytokine synthesis. Microbiol Rev 1996; 60: 316–341.
3. Gupta D, Kirkland TN, Viriyakosol S, Dziarski R. CD14 is a cell-activating
receptor for bacterial peptidoglycan. J Biol Chem 1996; 271:
23310–23316.
4. Pugin J, Heumann ID, Tomasz A, et al. CD14 is a pattern recognition
receptor. Immunity 1994; 1: 509–516.
5. Rietschel ET, Schletter J, Weidemann B, et al. Lipopolysaccharide and
peptidoglycan: CD14-dependent bacterial inducers of inflammation.
Microb Drug Resist 1998; 4: 37–44.
6. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptido-
glycan- and lipoteichoic acid-induced cell activation is mediated by toll-
like receptor 2. J Biol Chem 1999; 274: 17406–17409.
7. Heumann D, Glauser MP, Calandra T. Molecular basis of host-pathogen
interaction in septic shock. Curr Opin Microbiol 1998; 1: 49–55.
8. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and
future prospects. Immunol Today 1993; 14: 281–284.
9. Keglevic D, Ladesic B, Tomasic J, Valinger Z, Naumski R. Isolation
procedure and properties of monomer unit from lysozyme digest of
peptidoglycan complex excreted into the medium by penicillin-treated
Brevibacterium divaricatum mutant. Biochim Biophys Acta 1979; 585:
273–281.
10. Gabrilovac J, Tomasic J, Boranic M, Martin-Kleiner I, Osmak M. In vivo
and in vitro modulation of NK and ADCC activities of mouse spleen cells
by peptidoglycan monomer (PGM). Res Exp Med (Berl) 1989; 189:
265–273.
11. Rakocevic S, Silobrcic V. A peptidoglycan monomer as an antitumor agent
in mice: stimulation of phagocytosis by resident peritoneal macrophages
with peptidoglycan monomer. J Biol Response Mod 1988; 7: 6–10.
12. Sava G, Tomasic J, Hrsak I. Antitumor and metastatic activity of the
immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa
mammary carcinoma. Cancer Immunol Immunother 1984; 18:
49–53.
13. Muhvic´ D, El-Samalouti V, Flad HD, Radosevic-Stasic B, Rukavina D. The
involvement of CD14 in the activation of human monocytes by
peptidoglycan monomers. Mediat Inflamm 2001; 10: 155–162.
14. Ravlic-Gulan J, Radosevic-Stasic B, Trobonjaca Z, Petkovic M, Cuk M,
Rukavina D. On the role of T lymphocytes in stimulation of humoral
immunity induced by peptidoglycan-monomer linked with zinc. Int Arch
Allergy Immunol 1999; 119: 3–22.
15. Radosevic-Stasic B, Trobonjaca Z, Petkovic M, et al. Immunoregulating
effects of peptidoglycan monomer linked with zinc in adult mice. Int
Arch Allergy Immunol 1995; 106: 219–228.
16. Ravlic-Gulan J, Radosevic-Stasic B, Gulan G, Stimac D, Pavelic K,
Rukavina D. Immunoprotective properties of peptidoglycan monomer
linked with zinc in cholestatic jaundice. Int Arch Allergy Immunol
2000; 123: 354–364.
17. Radosevic-Stasic B, Ravlic-Gulan J, Trobonjaca Z, et al. Age-dependent
effects of peptidoglycan monomer linked with zinc on the generation of
suppressor macrophages in mice. Croatian Med J 1997; 38: 212–216.
18. Verbanac D, Milin C, Radosevic-Stasic B, et al. Tissue zinc dynamics
during the immune reaction in mice. Biol Trace Element Res 1998; 65:
97–108.
19. Iiai T, Watanabe H, Seki S, et al. Ontogeny and development of
extrathymic T cells in mouse liver. Immunology 1992; 77: 556–563.
20. Doherty DG, O’Farrelly C. Innate and adaptive lymphoid cells in the
human liver. Immunol Rev 2000; 174: 5–20.
I. Mrakovcic- ÆSutic´ et al.
134 Mediators of Inflammation · Vol 11 · 2002
21. Radosevic-Stasic B, Trobonjaca Z, Cuk M, Petkovic M, Rukavina D. Liver
regeneration in MHC class I deficient mice. Period Biol 1996; 98:
517–521.
22. Abo T. Extrathymic pathways of T-cell differentiation and immunomodu-
lation. Int Immunopharmaco l 2001; 1: 1261–1273.
23. Abo T, Watanabe H, Sato K, et al. Extrathymic T cells stand at an
intermediate phylogenetic position between natural killer cells and
thymus-derived T cells. Nat Immunol 1995; 14: 173–187.
24. Kawachi Y, Watanabe H, Moroda T, et al. Self-reactive T cell clones in a
restricted population of interleukin-2 receptor beta+ cells expressing
intermediate levels of the T cell receptor in the liver and other immune
organs. Eur J Immunol 1995; 25: 2272–2278.
25. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1. T
cells: development, specificity and function. Annu Rev Immunol 1997;
15: 535–562.
26. Watanabe H, Miyaji C, Kawachi Y, et al. Relationships between
intermediate TCR cells and NK1.1+ T cells in various immune organs.
NK1.1+ T cells are present within a population of intermediate TCR cells.
J Immunol 1995; 155: 2972–2983.
27. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells:
facts, functions and fallacies. Immunol Today 2000; 21: 573–583.
28. Gumperz JE, Brenner MB. CD1-specific T cells in microbial immunity.
Curr Opin Immunol 2001; 13: 471–478.
29. Sugita M, Moody DB, Jackman RM, et al. CD1 – a new paradigm for
antigen presentation and T cell activation. Clin Immunol Immunopa-
thol 1998; 87: 8–14.
30. Ulrichs T, Porcelli SA. CD1 proteins: targets of T cell recognition in innate
and adaptive immunity. Rev Immunogenet 2000; 2: 416–432.
31. Fairhurst RM, Wang CX, Sieling PA, Modlin RL, Braun J. CD1-restricted T
cells and resistance to polysaccharide-encapsulated bacteria Immunol
Today 1998; 19: 257–259.
32. Chiu YH, Jayawardena J, Weiss A, et al. Distinct subsets of CD1d-restricted
T cells recognize self-antigens loaded in different cellular compartments.
J Exp Med 1999; 189: 103–110.
33. Gumperz JE, Roy C, Makowska A, et al. Murine CD1d-restricted T cell
recognition of cellular lipids. Immunity 2000; 12: 211–221.
34. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma
delta T cells by nonpeptidic mycobacterial ligands. Science 1994; 264:
267–270.
35. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D,
a receptor for stress-inducible MICA. Science 1999; 285: 727–729.
36. Maksymowych WP, Kane KP. Bacterial modulation of antigen processing
and presentation. Microbes Infect 2000; 2: 199–211.
37. Fraker PJ, King LE. A distinct role for apoptosis in the changes in
lymphopoiesis and myelopoiesis created by deficiencies in zinc. FASEB J
2001; 15: 2572–2578.
38. Mocchegiani E, Muzzioli M, Giacconi R. Zinc and immunoresistance to
infection in aging: new biological tools. Trends Pharmacol Sci 2001; 22:
112–113.
39. Taylor CG, Giesbrecht JA. Dietary zinc deficiency and expression of T
lymphocyte signal transduction proteins. Can J Physiol Pharmacol
2000; 78: 823–828.
40. Prasad AS. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J
Infect Dis 2000; 182(Suppl 1): S62–S68.
41. Wellinghausen N. Immunobiology of gestational zinc deficiency. Br J
Nutr 2001; 85(Suppl 2): S81–S86.
42. Vales-Gomez M, Erskine RA, Deacon MP, Strominger JL, Reyburn HT. The
role of zinc in the binding of killer cell Ig-like receptors to class I MHC
proteins. Proc Natl Acad Sci USA 2001; 98: 1734–1739.
43. Rajagopalan S, Long EO. Zinc bound to the killer cell-inhibitory receptor
modulates the negative signalin human NK cells. J Immunol 1998; 161:
1299–1305.
44. Sundstrom M, Hallen D, Svensson A, Schad E, Dohlsten M, Abrahmsen L.
The co-crystal structure of staphylococcal enterotoxin type A with Zn2+
at 2.7 A resolution. Implications for major histocompatibility complex
class II binding. J Biol Chem 1996; 271: 32212–32216.
45. Truong-Tran AQ, Carter J, Ruffin RE, Zalewski PD. The role of zinc in
caspase activation and apoptotic cell death. Biometals 2001; 14:
315–330.
46. Fraker PJ, King LE. A distinct role for apoptosis in the changes in
lymphopoiesis and myelopoiesis created by deficiencies in zinc. FASEB J
2001; 15: 2572–2578.
47. Flad HD, Grage-Griebenow E, Petersen F, et al. The role of cytokines in
monocyte apoptosis. Pathobiology 1999; 67: 291–293.
48. Baran J, Weglarczyk K, Mysiak M, et al. Fas (CD95)–Fas ligand inter-
actions are responsible for monocyte apoptosis occurring as a result of
phagocytosis and killing of Staphylococcus aureus. Infect Immun 2001;
69: 1287–1297.
49. Moss JE, Aliprantis AO, Zychlinsky A. The regulation of apoptosis by
microbial pathogens. Int Rev Cytol 1999; 187: 203–259.
50. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The
apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J
2000; 19: 3325–3336.
51. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10:
399–415.
52. Carnaud C, Lee D, Donnars O, et al. Cutting edge: cross-talk between
cells of the innate immune system: NKT cellsrapidly activate NK cells. J
Immunol 1999; 163: 4647–4650.
Received 7 November 2001
Accepted 15 February 2002
Cytotoxicity by PGM-Zn activated lymphoid cells
Mediators of Inflammation · Vol 11 · 2002 135
